Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine

Journal of Clinical Virology

Volumn 53, Issue 3, 2012, Pages 239-243

  Rowhani Rahbar, Ali ^a,b   Alvarez, Frances B ^c   Bryan, Janine T ^a,c   Hughes, James P ^a   Hawes, Stephen E ^a   Weiss, Noel S ^a   Koutsky, Laura A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KAISER PERMANENTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Human papillomavirus type 16; Immune memory; Vaccines

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; TREATMENT DURATION;

ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOASSAY; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84856974035     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.009     Document Type: Article

References (19)

1. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927.
2. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006, 107:18-27.
3. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
4. De Carvalho N.S., Roteli-Martins C.M., Teieira J., Nahud P. Immunogenicity and safety of HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years. Presented at the 25th international papillomavirus conference 2009.
5. Rowhani-Rahbar A., Mao C., Hughes J.P., Alvarez F.B., Bryan J.T., Hawes S.E., et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009, 27:5612-5619.
6. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008, 109:S15-S21.
7. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25:4931-4939.
8. Dias D., Van Doren J., Schlottmann S., Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005, 12:959-969.
9. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115.
10. Poland G.A., Jacobson R.M., Koutsky L.A., Tamms G.M., Railkar R., Smith J.F., et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005, 80:601-610.
11. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24:5571-5583.
12. Christensen N.D., Cladel N.M., Reed C.A. Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 1995, 207:136-142.
13. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851.
14. Ward S.M., Phalora P., Bradshaw D., Leyendeckers H., Klenerman P. Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infect Dis 2008, 198:813-817.
15. Eklund C., Unger E.R., Nardelli-Haefliger D., Zhou T., Dillner J. International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine 2011, 10.1016/j.vaccine.2011.10.096.
16. Eklund C., Zhou T., Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48:4147-4155.
17. Ferguson M., Wilkinson D.E., Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009, 27:337-347.
18. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006, 17:517-521.
19. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 2006, 17:237-246.